Instead, less than two weeks after Klobuchar and two other senators asked the DOJ to investigate Mylan's seemingly deliberate drug classification missteps, it appears the feds have agreed to a $465 million settlement with the drug company, an agreement that includes no admission of wrongdoing. If you think that's a high price to pay, consider the fact that EpiPens alone netted the company $1 billion for each of the last two years. Or that, according to a letter from Centers for Medicare & Medicaid Acting Administrator Andrew Slavitt, on "multiple occasions" the federal authorities "expressly told Mylan that the product is incorrectly classified."